Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

Antonio Russo, Lara Felicioni, Olga Venditti, Alessandro Parisi, Paola Lanfiuti Baldi, Alessio Cortellini, Vincenzo Vicentini, Carla D’Orazio, Antonella Dal Mas, Roberto Vicentini, Katia Cannita, Giuseppe Calvisi, Corrado Ficorella, Fiamma Buttitta, Antonio Marchetti, Aldo V. Giordano

Risultato della ricerca: Articlepeer review

4 Citazioni (Scopus)

Abstract

Background: Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting interesting results in terms of received dose intensities (rDIs) and safety.Methods: We reported a retrospective update of 85 patients treated with FIrB/FOx, an intensive regimen of 5-fluorouracil, bevacizumab, and weekly alternate irinotecan and oxaliplatin, to confirm its feasibility in “real life”. Subgroup analyses were performed, particularly among patients treated with standard and modified FIrB/FOx (based on age, performance status, and/or comorbidities).Results: Overall, 3-month objective response rate (ORR) and 6-month ORR were 75.9% and 55.3%, respectively. Median progression-free survival (PFS) and median overall survival (OS) were 14.4 and 34.9 months, respectively. Among the patients treated with standard and modified regimens, 3-month ORR, PFS, and OS were 75.8% and 76% (P=1.0000), 14.4 and 14.4 months (P=0.8589), and 37.8 and 26.6 months (P=0.7746), respectively. Among the K/NRAS wild-type and K/NRAS mutant patients, 3-month ORR, PFS, and OS were 95.2% and 74.5% (P=0.0526), 15.3 and 14.4 months (P=0.8753), and 37.8 and 51.4 months (P=0.8527), respectively. The rDIs were ≥80% of full doses both in the standard and in the modified regimens subgroups. Cumulative G3/4 toxicities were neutropenia (14.1%), diarrhea (17.6%), asthenia (9.4%), vomiting (5.6%), and hypertension (16.5%).Conclusion: This update shows that intensive regimens such as FIrB/FOx are also feasible options for first-line treatment of mCRC patients in the “real-life” setting.
Lingua originaleEnglish
pagine (da-a)2159-2170
Numero di pagine12
RivistaOncoTargets and Therapy
Volume12
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Fingerprint Entra nei temi di ricerca di 'Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice'. Insieme formano una fingerprint unica.

Cita questo